28. Seeman E, Delmas PD, Hanley DA, Sellmayer D, Cheung AM Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microaechitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate. J Bone Mineral Res 2010; 25 (8): 1886–1894

29. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M for the A-TOP (Adequate Treatment for Osteoporosis) research group. Effects of Alendronate plus Alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02. Curr Med Res Opin 2011; 27 (6), 1273–1284

30. Reginster JY, Felsenberg D, Boonen S, Diez-Perlz A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delms PD, Meunier PJ. Effects of Long-term Strontium Ranelate Treatment on the Risk of Non-vertebral and Vertebral Fractures in Postmenopausal Osteoporosis. Arthritis & Rheumatism 2008; 58 (6): 1687–1695

31. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. für die Freedom-Studie. Denosumab zur Frakturprävention bei postmenopausalen Frauen mit Osteoporose. N Engl J Med 2009; 361: 756–765

32. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pissonia M et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007; 55:752–757.

33. Gaal J, Bender T, Varga J, Horvath I, Kiss J, Somogyi P, Suranyi P. Overcoming Resistance to Bisphosphonates through the Administration of Alfacalcidol: Results of a 1 year, open follow-up study. Rheumatol Int 2009, 30, (1): 25–31.

34. Frediani B, Allegri A, Bisogno S, Marcolongs R. Effects of combined treatment with calcitriol plus Alendronate on bone mass and bone turnover in post-menopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest. 1998;15:235–244.

35. Francis RM, Boyle IT, Moniz C, Sucliffe AM, Davis BS, Benstall GH, Cowan RA, Downes N. A Comparison of the Effects of Alfacalcidol Treatment and Vitamin D Supplementation on Calcium Absorption in Elderly Women with Vertebral Fractures. Osteoporos Int 1996; 284–290.

36. Nuti R, Bianchi G, Brandi ML, Caudarella R, D’Erasmo E, Fiori C, Isaia GC, Luisietto G, Muratore M, Oriente P, Ortolani S. Superiority of Alfacalcidol compared to Vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int 2006; 26: 445–453.

37. Kneer W, Schacht E. Stellenwert einer physiologishen Osteoporosetherapie mit Alfacalcidol. Orthopaedische Praxis 2002; 38(8): 551–556.

38. Dambacher MA, Dukas L, Felsenberg D, Hantzschel J, Lange U, Runge M, Scharla S, Sturm D. Schacht E. Osteoporose-Frakturen vorbeugen: Stellenwert der D-Hormon-Analoga. Therapiewoche 2005; 12: 328–331.

39. Schacht, E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Muskuloskelet Neuronal Interact. 2007; 7(2): 174–184.

40. Ringe JD, Schacht E. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int. 2007; 28: 103–111.

41. Schacht E, Ringe JD. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with Alfacalcidol and Alendronate: a prospective study. Arzneimittelforschung 2011;61(1):40–54.

42. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25 (11): 2267–94

Fussnoten

ZORG (Zürich Osteoporosis Research Group), Zollikerberg, Schweiz

WOZ (Westdeutsches Osteoporose Zentrum), Med. Klinik 4, Klinikum Leverkusen, Universität zu Köln, Deutschland

Praxis für Orthopädie, Stockach, Deutschland, Ambulantes osteologisches Schwerpunktzentrum DVO

DOI 10.328/oup.2012.0053-0059